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Abstract 
The PAC1 receptor and tissue transglutaminase (TG2) play important roles in neurite 
outgrowth and modulation of neuronal cell survival. In this study, we investigated the 
regulation of TG2 activity by the PAC1 receptor in retinoic acid-induced differentiating 
N2a neuroblastoma cells. TG2 transamidase activity was determined using an amine 
incorporation and a peptide cross linking assay. In situ TG2 activity was assessed by 
visualising the incorporation of biotin-X-cadaverine using confocal microscopy. TG2 
phosphorylation was monitored via immunoprecipitation and Western blotting. The role 
of TG2 in PAC1 receptor-induced cytoprotection and neurite outgrowth was investigated 
by monitoring hypoxia-induced cell death and appearance of axonal-like processes, 
respectively. The amine incorporation and protein crosslinking activity of TG2 increased 
in a time and concentration-dependent manner following stimulation with pituitary 
adenylate cyclase-activating polypeptide-27 (PACAP-27). PACAP-27 mediated increases 
in TG2 activity were abolished by the TG2 inhibitors Z-DON and R283 and by 
pharmacological inhibition of protein kinase A (KT 5720 and Rp-cAMPs), protein kinase C 
(Ro 31-8220), MEK1/2 (PD 98059), and removal of extracellular Ca2+. Fluorescence 
microscopy demonstrated PACAP-27 induced in situ TG2 activity. TG2 inhibition  blocked 
PACAP-27 induced attenuation of hypoxia-induced cell death and outgrowth of axon-like 
processes. TG2 activation and cytoprotection were also observed in human SH-SY5Y 
cells. Together, these results demonstrate that TG2 activity was stimulated downstream 
of the PAC1  receptor via a multi protein kinase dependent pathway. Furthermore, PAC1 
receptor-induced cytoprotection and neurite outgrowth are dependent upon TG2. These 
results highlight the importance of TG2 in the cellular functions of the PAC1 receptor. 
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1. Introduction 
Transglutaminases (TGs) are a family of Ca2+)-dependent enzymes that catalyse the 
post-translational modification of proteins (for extensive reviews see Nurminskaya and 
Belkin, 2012; Eckert et al., 2014). There are eight distinct catalytically active members 
of the TG family which exhibit differential expression (Factor XIIIa and TGs 1-7).  
The ubiquitously expressed TG2 is the most widely studied member of the TG family 
which is involved in the regulation of numerous cellular processes, including cell 
adhesion, migration, growth, survival, apoptosis, differentiation, and extracellular matrix 
organization (Nurminskaya and Belkin, 2012).  In neuronal cells, TG2 is involved in 
neural differentiation, neurite outgrowth and neuroprotection following cerebral 
ischaemia (Tucholski et al., 2001; Filiano et al., 2010; Vanella et al., 2015). 
Transglutaminase 2 (TG2) possesses multiple enzymic functions that include 
transamidation, protein disulphide isomerase and protein kinase activity (Gundemir et al., 
2012). The transamidase activity of TG2 is inhibited by GTP/GDP and evidence suggests 
that TG2 when bound to GTP/GDP functions as a G-protein (known as Gh; Mhaouty-Koja, 
2004), which is independent of its transamidase activity.  Indeed, several members of 
the G-protein coupled receptor (GPCR) family including the 1B-adrenergic receptor, 
thromboxane A2 receptor and oxytocin receptor couple to Gh when activated, promoting 
exchange of GDP for GTP (Gundemir et al., 2012). Activated Gh-GTP stimulates 
phospholipase C 1 promoting phosphoinositide hydrolysis and stimulating increases in 
intracellular Ca2+. 
The activity of TG2 and other TG family members can be regulated by protein kinases. 
For example, phosphorylation of TG2 by protein kinase A (PKA) inhibits its 
transamidating activity but enhances its kinase activity (Mishra et al., 2007). The 
transamidating activity of TG1 (keratinocyte transglutaminase) is enhanced by phorbol 
ester-induced stimulation of protein kinase C (PKC) and extracellular signal-regulated 
kinase 1/2 (ERK1/2; Bollag et al., 2005). These findings suggest that the activity of TG 
can be regulated by signaling pathways associated with GPCRs. However, the regulation 
of intracellular TG2 following stimulation of GPCRs is not well understood. Examples 
include muscarinic receptor-mediated increases in TG2 activity in SH-SY5Y cells (Zhang 
et al., 1998), 5-HT2A receptor-mediated transamidation of Rac1 in the rat A1A1v cortical 
cell line (Dai et al., 2008) and A1 adenosine receptor-mediated increases in TG2 
transamidase activity in rat H9c2 cardiomyoblasts (Vyas et al., 2016). 
Of particular interest to the current study is pituitary adenylate cyclase-activating 
polypeptide (PACAP), which is widely distributed in the brain and peripheral organs and 
displays high affinity for the PAC1 receptor (Vaudry et al., 2009).  The PAC1 receptor is a 
member of the GPCR superfamily which activates adenylyl cyclase/cAMP/PKA (via Gs-
protein coupling) and phospholipase C/DAG/PKC (via Gq-protein coupling) dependent 
signalling pathways (Dickson and Finlayson, 2009; Vaudry et al., 2009). The PAC1 
receptor also triggers the activation of several other protein kinase cascades such as 
ERK1/2, JNK1/2, p38 MAPK and PKB (Monaghan et al., 2008; May et al., 2010, Castorina 
et al. 2014). Since some of these protein kinase pathways are associated with 
modulation of TG activity (PKA, PKC and ERK1/2)  it is conceivable that the PAC1 
receptor regulates TG activity. Since mouse N2a neuroblastoma cells express PAC1 
receptors (Leliévre et al., 1998; Miura et al., 2013;) the primary aims of this study were 
(i) to determine whether the PAC1 receptor modulates TG2 activity in these cells and (ii) 
to assess the role of TG2 in PAC1 receptor-induced neuroprotection and neurite 
outgrowth The results obtained indicate that PAC1 receptor stimulation triggers TG2-
mediated amine incorporation and protein cross-linking activity in differentiating N2a and 
SH-SY5Y cells. Furthermore, inhibition of TG2 attenuates PAC1 receptor-induced 
cytoprotection and neurite outgrowth.  
 
 
  
2. Materials and Methods 
2.1. Materials 
Akt inhibitor XI, KT 5720, Ro-31-8220 and Rp-8-Cl-cAMPS (adenosine 3’,5’-cyclic 
monophosphorothioate, 8-chlro-, Rp-isomer) were purchased from Calbiochem (San 
Diego, CA). [Ala11,22,28]-VIP, Bay 55-9837, PACAP-27, PACAP 6-38, PD 98059, SB 203580, 
and SP 600 125 were obtained from Tocris Bioscience (Bristol, UK). All-trans retinoic acid, 
casein, Protease Inhibitor Cocktail (for use with mammalian cell and tissue extracts), 
Phosphatase Inhibitor Cocktail 2 and 3, ExtrAvidin®-HRP and ExtrAvidin®-FITC were 
obtained from Sigma-Aldrich Co. Ltd. (Gillingham, UK). The TG2 inhibitors Z-DON (Z-
ZON-Val-Pro-Leu-OMe) and R283, together with purified guinea-pig liver TG2 were 
obtained from Zedira GmbH (Darmstadt, Germany). DAPI was from Vector Laboratories 
Inc (Peterborough, UK). Fluo-8/AM was purchased from Stratech Scientific Ltd 
(Newmarket, UK). Biotin-TVQQEL was purchased from Pepceuticals (Enderby, UK). Biotin 
cadaverine (N-(5-aminopentyl)biotinamide) and biotin-X-cadaverine (5-([(N-
(biotinoyl)amino)hexanoyl]amino)pentylamine) were purchased from Invitrogen, UK. 
Dulbecco’s modified Eagle’s medium (DMEM), foetal bovine serum, trypsin (10×), L-
glutamine (200 mM), penicillin (10,000 U/ml)/streptomycin (10,000 g/ml) were 
purchased from BioWhittaker Ltd, UK. All other reagents were purchased from Sigma-
Aldrich Co. Ltd. (Gillingham, UK) and were of analytical grade. 
Antibodies were obtained from the following suppliers: monoclonal anti-phospho ERK1/2 
(Thr202/Tyr204) and polyclonal anti-tyrosine hydroxylase from Sigma-Aldrich; polyclonal 
anti-phospho PKB (Ser473), polyclonal anti-total PKB, monoclonal anti-total ERK1/2, 
monoclonal anti-phospho p38 MAPK, polyclonal anti-total p38 MAPK, monoclonal anti-
phospho JNK1/2, polyclonal anti-total JNK1/2 and polyclonal anti-cleaved caspase 3 from 
New England Biolabs Ltd (UK); polyclonal anti-human keratinocyte TG1 and polyclonal 
anti-human epidermal TG3 from Zedira GmbH (Darmstadt, Germany); monoclonal anti-
TG2 (CUB 7402) from Thermo Scientific (Leicestershire, UK); monoclonal anti-GAPDH, 
polyclonal anti-phosphoserine and polyclonal anti-phosphothreonine from Abcam 
(Cambridge, UK); polyclonal anti-choline acetyltransferase from Santa Cruz 
Biotechnology Inc (Heidelberg, Germany).  
 
2.2. Cell Culture 
Murine N2a and human SH-SY5Y neuroblastoma cells were obtained from the European 
Collection of Animal Cell Cultures (Porton Down, Salisbury, UK). Cells were cultured in 
DMEM supplemented with 2 mM L-glutamine, 10% (v/v) foetal bovine serum, penicillin 
(100 U/ml) and streptomycin (100 g/ml). Cells were maintained in a humidified incubator 
(95% air/5% CO2 at 37°C) until 70-80% confluent and sub-cultured (1:5 split ratio) every 
3-4 days. SH-SY5Y cells were sub-cultured using trypsin (0.05% w/v)/EDTA (0.02% w/v). 
Differentiation of N2a cells was induced by culturing cells in serum-free DMEM containing 1 
µM all-trans retinoic acid for 48 h, unless otherwise specified. Differentiation of SH-SY5Y 
cells was induced by culturing cells in serum-free DMEM containing 10 µM all-trans retinoic 
acid for 5 days. Experiments were performed on passage numbers 8-20 for N2a and 18-25 
for SH-SY5Y. 
 
2.3. cAMP accumulation assay 
N2a cells (5000 cells well-1) were seeded on a white 96 well microtitre plate, with clear 
bottomed wells (Corning; Fisher Scientific, Loughborough, UK) and induced to 
differentiate as described above. The medium was then removed and the monolayer 
treated with a range of concentrations of PACAP-27 for 20 min in serum-free DMEM (40 
µl well-1) in the presence of 20 mM MgCl2 and 500 µM 3-isobutyl-1-methylxanthine 
(IBMX). Following stimulation, cAMP levels within cells were determined using the cAMP-
Glo™ Max Assay kit (Promega; Southampton, UK). Briefly, 10 µl of cAMP detection 
solution was added to all wells and incubated for 20 min at room temperature. After 
incubation, Kinase-Glo® reagent (50 µl well-1) was added and incubated for 10 min at 
room temperature, following which luminescence levels across the plate were recorded 
using a plate-reading FLUOstar Optima luminometer (BMG Labtech Ltd, UK,). Treatment 
with forskolin (10 µM) was used as a positive control and the luminescence values were 
converted to cAMP levels using a cAMP standard curve (0-100 nM), according to the 
manufacturer’s instructions. 
 
2.4. Cell extraction for measurement of TG2 activity   
Time course profiles and concentration-response curves were obtained for PACAP-27. 
Where appropriate, cells were also pre-incubated for 30 min in medium with or without 
the protein kinase inhibitors Rp-cAMPs (PKA, 50 µM; de Wit et al., 1984), KT 5720 (PKA, 
5 µM; Kase et al., 1987),  Akt inhibitor XI (PKB/Akt, 100 nM; Barve et al., 2006), PD 
98059 (MEK1/2, 50 µM; Dudley et al., 1995), SP 600125 (JNK1/2, 20 µM; Bennett et al., 
2001), and Ro 31-8220 (PKC, 10 µM; Davies et al., 1989) prior to treatment with 100 
nM PACAP-27. The concentrations of protein kinase inhibitors employed in this study 
were in the range of values in the literature that are used to inhibit the cellular activity of 
these kinases: KT 5720 (2-10 µM; Werner et al., 2014; Mangiavacchi and Wolf, 2004); 
Rp-cAMPs (10-100 µM; Werner et al., 2014; Mangiavacchi and Wolf, 2004; Wang et al., 
2012; Pratt et al., 2016; Vallejo and Vallejo, 2002); Ro 31-8220 (1-10 µM; Lee et al., 
2013; Montejo-López et al., 2016), PD 98059 (10-50 µM; Sutter et al., 2004; Kim et al., 
2008), SP 600125 (20 µM; Hah et al., 2013; Kim et al., 2010) and Akt inhibitor XI (1 µM; 
Frampton et al.,2012; Rybchyn et al., 2011). In the case of less well known Akt inhibitor 
XI effects on PKB inhibition were verified by Western blot analysis. 
   Following stimulation, N2a and SH-SY5Y cells were rinsed twice with 2.0 ml of chilled 
PBS, lysed with 500 μl of ice-cold lysis buffer (50 mM Tris-HCl pH 8.0, 0.5% (w/v) 
sodium deoxycholate, 0.1% (v/v) Protease Inhibitor Cocktail, and 1% (v/v) Phosphatase 
Inhibitor Cocktail 2). Cell lysates were scraped and clarified by centrifugation at 4°C for 
10 min at 14000 x g prior to being assayed for TG activity using the biotin-labeled 
cadaverine incorporation assay (see below). Supernatants were collected and stored at -
80°C. 
   Protein levels were determined by the bicinchoninic acid (BCA) protein assay, based on 
the method of Smith et al. (1985), which was performed using a commercially available 
kit (Sigma-Aldrich, UK) using bovine serum albumin (BSA) as the standard. 
Transglutaminase activity was monitored by two different transamidase assays; amine 
incorporation and protein cross-linking.  
 
2.5. Biotin-labeled cadaverine incorporation assay  
The assay was performed as per the method described by Slaughter et al. (1992) with 
the modifications of Lilley et al. (1998). Briefly, 96-well microtitre plates were coated 
overnight at 4°C with 250 μl of N′,N′-dimethylcasein (10 mg ml-1 in 100 mM Tris-HCl, pH 
8.0). The plate was washed twice with distilled water and blocked with 250 μl of 3% 
(w/v) BSA in 100 mM Tris-HCl, pH 8.0 and incubated for 1 h at room temperature. The 
plate was washed twice before the application of 150 µl of either 6.67 mM calcium 
chloride and or 13.3 mM EDTA (used to deplete calcium and suppress TG activity) assay 
buffer containing 225 µM biotin cadaverine (a widely used substrate to monitor TG amine 
incorporating activity) and 2 mM 2-mercaptoethanol. The reaction was started by the 
addition of 50 μl of samples or positive control (50 ng/well of guinea-pig liver TG2) and 
negative control (100 mM Tris-HCl, pH 8.0). After incubation for 1 h at 37°C plates were 
washed as before. Then, 200 μl of 100 mM Tris-HCl pH 8.0 containing 1% (w/v) BSA and 
ExtrAvidin®-HRP (1:5000 dilution) was added to each well and the  plate incubated at 
37°C for 45 min then washed as before. The plate was developed with 200 μl of freshly 
made developing buffer (7.5 µg ml-1 3,3’,5,5’-tetramethylbenzidine (TMB) and 0.0005% 
(v/v) H2O2 in 100 mM sodium acetate, pH 6.0) and incubated at room temperature for 
15 min. The reaction was terminated by adding 50 μl of 5 M sulphuric acid and the 
absorbance read at 450 nm. One unit of TG2 was defined as a change in absorbance of 
one unit h-1. Each experiment was performed in triplicate. 
 
2.6. Biotin-labeled peptide-cross-linking assay   
The assay was performed according to the method of Trigwell et al. (2004) with minor 
modifications. Microtitre plates (96-well) were coated and incubated overnight at 4°C 
with casein at 1.0 mg ml-1 in 100 mM Tris-HCl pH 8.0 (250 μl per well). The wells were 
washed twice with distilled water, before incubation at room temperature for 1 h with 
250 μl of blocking solution (100 mM Tris-HCl pH 8.0 containing 3% (w/v) BSA). The 
plate was washed twice before the application of 150 µl of either 6.67 mM calcium 
chloride and or 13.3 mM EDTA assay buffer containing 5 μM biotin-TVQQEL and 2mM 2-
mercaptoethanol. The reaction was started by the addition of 50 μl of samples or 
positive control (50 ng/well of guinea-pig liver TG2) and negative control (100 mM Tris-
HCl, pH 8.0) and allowed to proceed for 1 h at 37°C. Reaction development and 
termination were performed as described for biotin-cadaverine assays. One unit of TG2 
was defined as a change in absorbance of one unit h-1. Each experiment was performed 
in triplicate. 
 
2.7. Hypoxia-induced cell death 
Differentiating N2a and SH-SY5Y cells in glucose-free and serum-free DMEM (Gibco™, 
Life Technologies Ltd, Paisley, UK) were exposed to hypoxia using a hypoxic incubator (5% 
CO2/1% O2 at 37°C) in which O2 was replaced by N2.  
 
2.8. Cell viability assays 
N2a and SH-SY5Y cells were plated in 24-well flat bottomed plates (15,000 cells/well) and 
differentiated for 48 h, before cell viability was determined by measuring the reduction of 
MTT (Mosmann et al., 1983). The amount of DMSO-solubilised reduced formazan product 
was determined by measurement of absorbance at a wavelength 570 nm. Alternatively, 
cells were plated in 96-well flat bottomed plates (5,000 cells per well) and differentiated 
for 48 h. Following normoxia/hypoxia exposure, the activity of lactate dehydrogenase 
(LDH) released into the culture medium was detected using the CytoTox 96®non-
radioactive cytotoxicity assay (Promega, Southampton, UK) with measurement of 
absorbance at 490 nm. 
 
2.9. Outgrowth of axon-like processes 
The outgrowth of axon-like processes in N2a cells was assessed as described previously 
(Hargreaves et al., 2006). N2a cells were seeded in 24-well plates (25,000 cells/well) 
and incubated for 24 h in growth medium prior to treatment with PACAP-27 (100 nM) in 
serum-free DMEM for 24 or 48 h. After stimulation, the cells were washed with ice cold 
phosphate buffered saline (PBS) then fixed in 90% (v/v) methanol in PBS at -20˚C for 
15 min. After washing, the cells were stained for 1 min at room temperature with 
Coomassie brilliant blue, washed with PBS then with distilled water. The outgrowth of 
axon-like processes was morphologically assessed using an inverted light microscope. 
Five randomly selected fields, containing at least 200 cells,  were examined in each well.  
The total number of cells and the number of axon-like processes, defined as extensions 
greater than two cell body diameters in length with an extension foot (Keilbaugh et al., 
1991) were recorded.  
 
2.10. Western blot analysis  
Protein extracts (15-20 μg per lane) were separated by SDS-PAGE (10% w/v 
polyacrylamide gel) using a Bio-Rad Mini-Protean III system. Proteins were transferred 
to nitrocellulose membranes in a Bio-Rad Trans-Blot system using 25 mM Tris, 192 mM 
glycine pH 8.3 and 20% (v/v) MeOH). Following transfer, the membranes were washed 
with Tris-buffered saline (TBS) and blocked for 1 h at room temperature with 3% (w/v) 
skimmed milk powder in TBS containing 0.1% (v/v) Tween-20. Blots were then 
incubated overnight at 4oC in blocking buffer with primary antibodies to the following 
targets (1:1000 dilutions unless otherwise indicated): phospho-specific ERK1/2, 
phospho-specific PKB (1:500), phospho-specific p38 MAPK, phospho-specific JNK (1:500), 
cleaved active caspase-3 (1:500), GAPDH, TG1, TG2 or TG3. The primary antibodies 
were removed and blots washed three times for 5 min in TBS/Tween 20. Blots were then 
incubated for 2 h at room temperature with the appropriate secondary antibody (1:1000) 
coupled to horseradish peroxidase (New England Biolabs Ltd; UK) in blocking buffer. 
Following removal of the secondary antibody, blots were extensively washed as above 
and developed using the Enhanced Chemiluminescence Detection System (Uptima, 
Interchim, France) and quantified by densitometry using Advanced Image Data Analysis 
Software (Fuji; version 3.52). The uniform transfer of proteins to the nitrocellulose 
membrane was routinely monitored by transiently staining the membranes with Ponceau 
S stain prior to application of the primary antibody. When assessing protein kinase 
phosphorylation samples from each experiment were also analysed on separate blots 
using primary antibodies that recognise total ERK1/2, PKB, p38 MAPK and JNK1/2 (all 
1:1000 dilution) in order to confirm the uniformity of protein loading. 
 
2.11. Visualisation of in situ TG2 activity and neuronal markers 
N2a cells were seeded on 8-well chamber slides (15,000 cells well-1) and differentiated 
for 48 h in serum-free DMEM containing retinoic acid or PACAP-27 (100 nM). The 
medium was then removed, monolayer gently washed with PBS and slides incubated for 
6 h with 1 mM biotin-X-cadaverine (a cell permeable TG2 substrate; Perry et al., 1995) 
in serum-free DMEM experimentation. Where appropriate, cells were treated for 1 h with 
TG2 inhibitors Z-DON (150 µM) or R283 (200 µM) before the addition of 100 nM PACAP-
27. Following stimulation, cells were fixed with 3.7 % (w/v) paraformaldehyde and 
permeabilised with 0.1% (v/v) Triton-X100 both in PBS for 15 min at room temperature. 
After washing, cells were blocked with 3% (w/v) BSA for 1 h at room temperature and 
the transglutaminase mediated biotin-X-cadaverine labeled protein substrates detected 
by (1:200 v/v) FITC-conjugated ExtrAvidin® (Sigma-Aldrich). For the visualisation of 
neuronal markers fixed cell monolayers were incubated overnight at 4oC with rabbit anti-
choline acetyltransferase antibody (1:200) or mouse anti-tyrosine hydroxylase antibody 
(1:200) in 3% (w/v) BSA. Unbound primary antibody was then removed, and  the cells 
washed three times for 5 min with PBS. Cells were then incubated for 2 h at 37oC in a 
humidified chamber with either goat anti-mouse or anti-rabbit FITC-conjugated 
immunoglobulin G (Abcam, Cambridge, UK) diluted 1:1000 in 3% (w/v) BSA. The 
chamber slide was subsequently washed three times for 5 min with PBS, air-dried and 
mounted with Vectashield medium (Vector Laboratories Ltd, Peterborough, UK) 
containing DAPI counterstain for nuclei visualisation. Finally slides were sealed using 
clear, colourless nail varnish and stained cells visualised using a Leica TCS SP5 II 
confocal microscope (Leica Microsystems, GmbH, Manheim, Germany) equipped with a 
20x air objective. Optical sections were typically 1-2 µm and the highest fluorescence 
intensity values were acquired and fluorescence intensity relative to DAPI stain 
quantified for each field of view. Saturation was avoided using the look-up Table overlay 
provided by the software.  Image analysis and quantification were carried out using Leica 
LAS AF software.   
 
 
2.12. Measurement of intracellular calcium 
N2a cells were plated in 24-well flat-bottomed plates (15,000 cells well-1) and 
differentiated for 48 h. Cells were loaded with Fluo-8 AM (5 µM, 30-40 min) before 
mounting on the stage of an Leica TCS SP5 II confocal microscope (Leica Microsystems, 
GmbH, Manheim, Germany) equipped with a 20x air objective. Cells were incubated at 
37°C using a temperature controller and micro incubator (The Cube, Life Imaging 
Services, Basel, Switzerland) in the presence of imaging buffer (134 mM NaCl 134, 6 mM 
KCl 6, 1.3 mM CaCl2 1 mM MgCl2 1, 10 mM HEPES, and 10 mM glucose; pH 7.4). Using 
an excitation wavelength of 490 nm , emissions over 514 nm were recorded. Images 
were collected every 1.7 s for 10 min. Relative increases in intracellular Ca2+ were 
defined as F/F0 where F was the fluorescence at any given time, and F0 was the initial 
basal level of Ca2+. 
 
 
2.13. Determination of TG2 phosphorylation 
Following stimulation, differentiated N2a cells were rinsed twice with 2.0 ml of chilled 
PBS and lysed with 500 μl of ice-cold lysis buffer (2 mM EDTA, 1.5 mM MgCl2, 10% (v/v) 
glycerol, 0.5% (v/v) IGEPAL, 0.1% (v/v) Protease Inhibitor Ccocktail, and 1% (v/v) 
Phosphatase Inhibitor Cocktail 2 and 3 in PBS). Cell lysates were clarified by 
centrifugation (4°C for 10 min at 14000 x g), after which 500 µg of supernatant protein 
were incubated overnight at 4°C with 2 µg of anti-TG2 monoclonal antibody or IgG. 
Immune complexes were precipitated using Pierce™ Classic Magnetic IP/Co-IP Kit 
(Loughborough, UK). The precipitates were resolved by SDS-PAGE and Western blotting, 
then probed using anti-phosphoserine or anti-phosphothreonine antibodies (1:1000). 
Antibody reactivity was visualised by ECL and quantified densitometrically, as described 
above. 
 
2.14. Statistical analysis 
All graphs and statistics (one-way ANOVA followed by Dunnet's multiple comparison test 
and two-way ANOVA for group comparison) were performed using GraphPad Prism® 
software (GraphPad Software, Inc., USA). Agonist EC50 values (concentration of agonist 
producing 50% of the maximal stimulation) were obtained by computer-assisted curve 
fitting using GraphPad Prism® software. Agonist p[EC50] values were subsequently 
calculated as the negative logarithm to base 10 of the EC50. Results represent mean ± 
S.E.M. and p values <0.05 were considered statistically significant. 
  
3. Results 
 
3.1. Characterisation of cholinergic neuronal phenotype and TG expression 
pattern in N2a cells 
Mouse N2a neuroblastoma cells can be differentiated into various neuronal types 
dependent upon the method used (Manabe et al., 2005; Tremblay et al., 2010). For 
example, serum withdrawal in the presence of retinoic acid induces differentiation into 
cholinergic neurons, whereas dibutyryl cAMP promotes the development of dopaminergic 
neurons (Manabe et al., 2005; Tremblay et al., 2010). In this study N2a cells were 
induced to differentiate using retinoic acid in order to avoid potential problems using 
dibutyryl cAMP when assessing functional responses mediated by the Gs-protein coupled 
PAC1 receptor. Immunocytochemical staining indicated that expression of the cholinergic 
neuronal marker, choline acetyltransferase increased markedly after 48 h confirming 
that retinoic acid promotes differentiation of N2a cells into cholinergic neurons (Fig 1A 
and B).  
   Western blot analysis was performed to compare the expression of TG isoforms in 
mitotic and differentiating N2a cells. TG1, TG2 and TG3 expression increased 
significantly in N2a cells following differentiation for 48 h with 1 µM all-trans retinoic acid 
(Fig. 1C and D). These observations are in agreement with previous studies (Condello et 
al., 2008).  
 
3.2. Effect of PAC1 receptor activation on TG2 activity  
PACAP-27 induced a robust increase in cAMP accumulation (EC50 = 4.0  1.3 nM;  
p[EC]50  = 8.5  0.2; n=3) in retinoic acid-induced differentiating N2a cells (Fig. 2).  The 
selective VPAC1 and VPAC2 agonists, [Ala11,22,28]-VIP (1 µM) and Bay 55-9837 (1 µM) 
respectively, had no significant effect on cAMP accumulation (data not shown). PACAP-27 
treatment produced transient increases in TG2 catalysed biotin-cadaverine incorporation 
and protein cross-linking activity, peaking at 10 min (Fig. 3A and C). Furthermore, as 
shown in Fig. 3, PACAP-27 stimulated concentration-dependent increases in biotin-amine 
incorporation activity (EC50 = 0.08  0.01 nM; p[EC50] = 10.1  0.1; n=5) and protein 
cross-linking activity (EC50 = 0.4  0.2 nM; p[EC50] = 9.7  0.2; n=6). The selective PAC1 
receptor antagonist PACAP 6-38 attenuated PACAP-27 induced biotin-amine 
incorporation activity (Fig. 4A) and protein cross-linking activity (Fig. 4B). The selective 
VPAC1 and VPAC2 agonists, [Ala11,22,28]-VIP (1 µM) and Bay 55-9837 (1 µM) respectively, 
had no significant effect on TG2 activity (data not shown). Overall, these data indicate 
that the PAC1 receptor is functionally expressed and stimulates TG2-mediated 
transamidase activity in differentiated N2a cells. 
 
3.3. Effect of TG2 inhibitors on PAC1 receptor induced TG2 activity 
To confirm that TG2 is responsible for PAC1 receptor-mediated transglutaminase activity 
in differentiating N2a cells, two structurally different cell permeable TG2 specific 
inhibitors were tested; R283 (a small molecule; Freund et al., 1994) and Z-DON 
(peptide-based; Schaertl et al., 2010). N2a cells were pre-treated for 1 h with Z-DON 
(150 µM) or R283 (200 µM) prior to stimulation with PACAP-27 for 10 min. Both 
inhibitors completely blocked PACAP-27-induced TG-mediated amine incorporation (Fig. 
4C) and protein cross-linking activity (Fig. 4D). It is important to note that despite these 
TG2 inhibitors being cell-permeable, inhibition of cellular TG2 is only achieved at 
concentrations significantly above their IC50 value versus purified enzyme (Schaertl et al., 
2010; Freund et al., 1994). Overall, these data indicate that TG2 is the TG isoform 
activated by the PAC1 receptor. 
 
3.4. The effect of protein kinase inhibitors on PAC1 receptor-induced TG2 
activity 
Pre-treatment with the PKA inhibitors KT 5720 (5 µM)  and Rp-cAMPs (50 µM) 
completely abolished PACAP-27-induced amine incorporation (Fig. 4E) and protein cross-
linking activity (Fig. 4F), confirming the involvement of PKA in TG2 activation via the 
PAC1 receptor.  
  Modulation of protein kinase activity following PAC1  receptor activation was assessed by 
Western blotting using phospho-specific antibodies that recognise phosphorylated motifs 
within activated ERK1/2 (pTEpY), p38 MAPK (pTGpY), JNK (pTPpY) and PKB (S473).  PACAP-
27 (100 nM) stimulated significant increases in ERK1/2 (Fig. 5A), PKB (Fig. 5B) and JNK1/2 
(Fig. 5C) phosphorylation in differentiating N2a cells. As expected PACAP-27-mediated 
increases in ERK1/2, PKB and JNK1/2 phosphorylation were inhibited by PD 98059 (50 µM; 
MEK1/2 inhibitor; Fig. 5A), Akt inhibitor XI (0.1, 1 µM and 10 µM; PKB inhibitor; Fig. 5B) 
and SP 600125 (20 µM; JNK1/2 inhibitor; Fig. 5B), respectively. No significant increases in 
p38 MAPK phosphorylation were observed following PACAP-27 (100 nM for 10 min) 
treatment (data not shown). PACAP-27–induced increases in ERK1/2 were also 
attenuated by KT 5720 (5 µM; PKA inhibitor; Fig. 6A) and Ro 31-8220 (10 µM; PKC 
inhibitor; Fig. 6B), but not following removal of extracellular Ca2+ (Fig. 6C). In summary, 
these data have shown that PAC1 receptor activation in differentiating N2a cells triggers 
robust increases in ERK1/2, PKB and JNK1/2 phosphorylation and that ERK1/2 activation 
is PKA and PKC dependent.  
  The role of ERK1/2, PKB, PKC and JNK1/2 in PAC1 receptor-induced TG2 activation was 
determined using pharmacological inhibitors of these protein kinases. PACAP-27-induced 
transglutaminase-mediated amine incorporation activity and protein cross-linking activity 
were inhibited by PD 98950, Ro 318220, and Akt inhibitor XI, suggesting the involvement 
of ERK1/2, PKC and PKB, respectively, in PAC1 receptor-mediated TG2 responses (Fig. 7 
A-D). In contrast, SP 6000125 attenuated PACAP-27-induced protein cross-linking 
activity (Fig. 7F) but was without effect on TG2-mediated amine incorporation (Fig. 7E). 
Finally, PD 98059, Ro 31-8220, Akt inhibitor XI, and SP 600125 had no significant effect 
on purified guinea pig liver TG2 activity (data not shown). Overall, these data suggest 
that the PAC1 receptor stimulates TG2 activity in differentiating N2a cells via a multi 
protein kinase dependent pathway.  
 
3.5. Visualisation of in situ TG2 activity following PACAP treatment 
Biotin-X-cadaverine, is a cell penetrating primary amine, which enables the in situ 
visualisation of endogenous protein substrates of TG2, when combined with FITC-
ExtrAvidin® (Lee et al. 1993). PACAP-27 (100 nM) induced a time dependent and 
concentration-dependent (EC50 = 6.7  3 nM; pEC50 = 8.3  0.2; n=3) increase in the 
incorporation of biotin-X-cadaverine into endogenous protein substrates of TG2 (Fig. 8). 
Finally, the in situ responses to PACAP-27 were attenuated by the PAC1 antagonist PACAP 
6-38 and the TG2 inhibitors ZDON and R283 (Fig. 8). Overall, these data indicate a 
similar pattern of TG2 activation in live cells. 
 
3.6. The role of Ca2+ in PAC1 receptor induced TG2 activity  
PACAP-27 (100 nM) triggered a robust increase in intracellular Ca2+ that was abolished in 
the absence of extracellular Ca2+ (Fig. 9A and B).  The role of extracellular Ca2+ in TG2 
activation was assessed in the absence of extracellular Ca2+ using nominally Ca2+-free 
Hanks/HEPES buffer containing 0.1 mM EGTA. Removal of extracellular Ca2+ abolished 
PACAP-27-induced TG2 activation (Fig. 9C and D). These observations suggest that PAC1 
receptor-induced TG2 activation is dependent upon extracellular Ca2+.  
 
3.7. Phosphorylation of TG2 following PAC1 receptor activation 
The effect of PAC1 receptor activation on the phosphorylation status of TG2 was 
monitored via immunoprecipitation of TG2 followed by  SDS-PAGE and Western blot 
analysis using anti-phosphoserine and anti-phosphothreonine antibodies. PACAP-27 (100 
nM) triggered a robust increase in the levels of TG2 phosphoserine and 
phosphothreonine (Fig. 10). Pre-treatment with PD 98059 (50 µM; Fig. 10) and KT 5720 
(5 µM; Fig. 11) attenuated PACAP-27 mediated increases in TG2 phosphorylation. In 
contrast, Ro 318220 (10 µM) had no significant effect (data not shown). Finally, removal 
of extracellular Ca2+ partially attenuated PACAP-27-induced TG2 phosphorylation (data 
not shown). These data indicate that activation of the PAC1 receptor promotes robust 
increases in TG2 phosphorylation. 
 
3.8. Role of TG2 in PAC1 receptor-induced cell survival and neurite outgrowth 
The role of TG2 in  PAC1 receptor-induced cell survival was determined in differentiating 
N2a cells following exposure of cells to simulated hypoxia (1% O2 in glucose-free and 
serum-free medium). Initial experiments determined the time course of simulated 
hypoxia-induced cell death in differentiated N2a cells. Exposure of cells to simulated 
hypoxia (1% O2) resulted in a time dependent decrease in MTT reduction, an increase in 
LDH release and activation of caspase 3 (Fig. 12). A time period of 8 h hypoxia was used 
in subsequent experiments.  Pre-treatment with PACAP-27 (100 nM; 10 min) 
significantly attenuated hypoxia-induced decrease in MTT reduction, release of LDH and 
activation of caspase-3 (Fig. 13).  Treatment with PACAP 6-38 (100 nM; 30 min) 
reversed PACAP-27 induced protection confirming the role of the PAC1 receptor. Finally, 
the TG2 inhibitors R283 and Z-DON attenuated PACAP-27 induced cell survival (Fig. 14). 
To validate these observations in another cell model the role of TG2 in  PAC1 receptor-
induced cell survival in human SH-SY5Y neuroblastoma cells was also investigated. 
Initial experiments demonstrated that PACAP-27 treatment produced transient increases 
in TG2 catalysed biotin-cadaverine incorporation and protein cross-linking activity, 
peaking at 30 min (Fig. 15A and C). Furthermore, as shown in Fig. 15, PACAP-27 
stimulated concentration-dependent increases in biotin-amine incorporation activity 
(EC50 = 2.2  1.0 nM;  p[EC50] = 8.9  0.4; n=3) and protein cross-linking activity (EC50 
= 1.3  0.5 nM; p[EC50] = 9.0  0.2; n=3). Exposure of SH-SY5Y cells to simulated 
hypoxia (1% O2) resulted in a time dependent decrease in MTT reduction, an increase in 
LDH release and activation of caspase 3 (data not shown), with 8 h used in subsequent 
experiments. As shown in Fig. 16, pre-treatment with PACAP-27 (100 nM; 10 min) 
significantly attenuated hypoxia-induced decrease in MTT reduction, release of LDH and 
activation of caspase-3 in SH-SY5Y cells (Fig. 16).  Furthermore, PACAP 6-38 (100 nM; 
30 min) reversed PACAP-27 induced protection confirming the role of the PAC1 receptor 
in human SH-SY5Y cells (Fig. 16A to D). Finally, the TG2 inhibitors R283 and Z-DON 
attenuated PACAP-27 induced cell survival (Fig. 16E to G). Overall, these results 
demonstrate a role of TG2 in PAC1 receptor-induced cell survival in both mouse N2a and 
human SH-SY5Y cells. 
  The role of TG2 in PAC1 receptor induced neurite outgrowth was assessed by 
monitoring the outgrowth of axon-like processes  following 24 and 48 h treatment with 
PACAP-27 (100 nM). The TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) attenuated 
outgrowth of axon-like processes following 24 h (data not shown) and 48 h treatment 
with PACAP-27, confirming the involvement of TG2 (Fig. 17). These data confirm a role 
for TG2 in PAC1 receptor mediated neurite outgrowth.   
4. Discussion 
The data in this report collectively suggest that PAC1 receptor-mediated cell survival and 
neurite outgrowth are mediated by TG2, consistent with the view that TG2-mediated 
amine incorporation and protein cross-linking play important roles in these events.  
  
4.1. In vitro modulation of TG2 transamidation activity by the PAC1 receptor 
Although the PAC1 receptor is expressed in mitotic N2a cells (Leliévre et al., 1998; Miura 
et al., 2013) its functional expression in differentiating N2a cells has to our knowledge 
not been reported. Hence, this study has demonstrated for the first time functional 
expression of the PAC1 receptor in N2a cells induced to differentiate with retinoic acid.  
The neuropeptide PACAP mediates neurite outgrowth and neuroprotection; however, it is 
not known if these events involve PAC1 receptor-induced TG2 activation (Monaghan et al., 
2008; Manecka et al., 2015; Jóźwiak-Bębenista et al., 2015). TG2 can catalyse two 
types of transamidation, namely (i) intra-, and/or inter-molecular covalent cross-links 
between protein-bound glutamine and protein-bound lysine residues, and (ii) cross-links 
between primary amines and protein-bound glutamine (Nurminskaya and Belkin, 2012). 
In this study the PAC1 receptor agonist PACAP-27 triggered time- and concentration-
dependent increases in TG2-mediated biotin-cadaverine incorporation and protein cross-
linking activity in differentiating N2a cells. The EC50 values for PACAP-27 mediated 
transglutaminase-catalysed amine incorporation (0.08 nM) and protein cross-linking 
activity (0.4 nM) are in-line with the affinity of PACAP-27 for the PAC1 receptor (Dickson 
et al., 2006; Dickson and Finlayson, 2009; Harmar et al., 2012). Furthermore, PACAP-
27-induced TG2 activity was blocked by the PAC1  receptor antagonist PACAP 6-38 
(Robberecht et al., 1992). Overall these data suggest that activation of TG2 by PACAP-
27 is mediated via the PAC1 receptor. It is important to note that PACAP 6-38 also 
displays high affinity for the VPAC2 receptor (Dickinson et al.,1997); however, since the 
VPAC2 agonist Bay 55-9837 did not trigger TG2 activity the effects of PACAP 6-38 are 
mediated entirely via the PAC1 receptor. Finally, the PAC1 receptor-induced increases in 
TG activity were inhibited by R283 and Z-DON, confirming that the observed increases in 
TG activity were via TG2.  
   At present, very little is known regarding the regulation of TG2 enzymic activity by 
GPCRs. Examples in the literature include muscarinic receptor-mediated increases in TG2 
activity in SH-SY5Y cells (Zhang et al., 1998) and 5-HT2A receptor-mediated 
transamidation (TG-catalyzed) of the small G-protein Rac1 in the rat cortical cell line 
A1A1v (Dai et al., 2008). The study by Zhang et al. (1998) measured in situ TG2 activity 
(polyamine incorporation) triggered by the non-selective muscarinic agonist carbachol, 
whereas, Dai et al. (2008) reported TG2 catalysed incorporation of 5-hydroxytryptamine 
into Rac1. 5-HT2A receptor-mediated incorporation of 5-HT into the small GTPases RhoA 
and Rab4 has also been observed in platelets (Walther et al., 2003). It was suggested 
that 5-HT2A and muscarinic receptor-mediated release of Ca2+ from intracellular Ca2+ 
stores  may be responsible for triggering TG transamidating activity (Zhang et al., 1998; 
Walther et al., 2003). Our recent studies have shown that the Gi/o-protein coupled A1 
adenosine receptor stimulates TG2 activation in H9c2 cardiomyocyte-like cells (Vyas et 
al., 2016). Since TG2 transamidase activity modulates protein function by cross-linking 
and incorporation of small molecule mono- and polyamines into protein substrates, it is 
likely that activation of TG2 by GPCRs plays a major role in the regulation of cellular 
function (Nurminskaya and Belkin, 2012; Eckert et al., 2014). 
 
4.2. Role of Ca2+ in PAC1 receptor-mediated TG2 activation 
The transamidating activity of TG2 is dependent upon Ca2+, which promotes the “open” 
form of TG2 and negates the inhibitory actions of the nucleotides GTP, GDP and ATP 
(Király et al., 2011). Previous studies have shown that release of Ca2+ from intracellular 
Ca2+ stores or influx of extracellular Ca2+ is linked to TG activation in response to GPCR 
stimulation (Zhang et al., 1998; Walther et al., 2003; Vyas et al., 2016). The data 
presented in the current work indicate that PAC1 receptor-induced transamidase activity 
is dependent upon extracellular Ca2+. Previous studies have shown that the PAC1 
receptor promotes Ca2+ mobilization from intracellular stores and Ca2+ influx via N-type 
calcium channels (Basille-Dugay et al., 2013) in rat cerebellar granule cells. In this study, 
PACAP-27-triggered Ca2+ responses were abolished in the absence of extracellular Ca2+ , 
which is indicative of Ca2+ influx. Clearly, further studies are required to determine the 
mechanism(s) of PAC1 receptor-induced Ca2+ influx in differentiated N2a cells and its role 
in TG2 activation. It is interesting to note that changes in intracellular [Ca2+] required for 
TG2 transamidating activity are typically in the order 3-100 µM (Király et al., 2011). 
However, there is growing evidence that intracellular [Ca2+] can reach levels sufficient to 
activate TG2, for example in calcium microdomains that occur near the cell membrane 
following the opening of voltage gated Ca2+ channels or near internal stores  (Berridge, 
2006; Király et al., 2011). Alternatively, the role of Ca2+ in PAC1 receptor-induced TG2 
activation may require the sensitization of TG2 to low levels of intracellular [Ca2+]. For 
example, interaction of TG2 with protein binding partners and/or membrane lipids have 
been proposed to induce a conformational change that promotes activation at low levels 
of intracellular [Ca2+] (Király et al., 2011).  
 
4.3. Role of protein kinases in PAC1 receptor-mediated TG2 activation 
The phosphorylation of TG2 by PKA inhibits its transamidating activity but augments its 
kinase activity (Mishra et al. 2007). These contrasting effects on TG2 activity were 
obtained using histidine-tagged TG2 immobilized on nickel-agarose and incubated with 
the catalytic subunit of PKA. In this study the PKA inhibitors KT 5720 and Rp-cAMPs 
completely blocked PACAP-27-induced TG2 transamidating activity, which reflects PAC1 
receptor signaling via cAMP/PKA. The PAC1 receptor also activates PLC/DAG/PKC (via Gq-
protein coupling) signalling and hence we determined the role of PKC. The broad 
spectrum PKC inhibitor Ro 318220 inhibited PACAP-27-induced TG2 activity, indicating 
that Gq-protein coupling is involved in PAC1 receptor-mediated TG2 activation. The PAC1 
receptor also activates ERK1/2, JNK1/2, p38 MAPK and PKB (Monaghan et al., 2008; 
May et al., 2010, Castorina et al., 2014). In this study we observed PACAP-27-induced 
activation of ERK1/2, JNK1/2, and PKB but not p38 MAPK. The MEK1/2 (upstream 
activator of ERK1/2) inhibitor PD 98059 blocked PACAP-27-induced TG2 activity, 
suggesting a prominent role for ERK1/2. These observations are comparable to A1 
adenosine receptor-mediated activation of TG2 in H9c2 cells, which was also sensitive to 
PKC and ERK1/2 inhibition (Vyas et al., 2016). In transfected HEK293 cells, PAC1 
receptor-induced ERK1/2 is dependent upon calcium influx and PLC/DAG/PKC (May et al., 
2014) and hence the inhibition of PACAP-27-induced TG2 by removal of extracellular 
Ca2+ and inhibition of PKC may reflect their up-stream  role(s) in ERK1/2 activation. In 
the current study, PAC1 receptor-induced ERK1/2 activation is independent of Ca2+ influx  
and partially sensitive to PKC inhibition. Similarly, PKA can activate ERK1/2 (Stork and 
Schmitt, 2002) and therefore the effect of PKA inhibitors on PAC1 receptor TG2 activation 
may also reflect the up-stream  role of PKA in ERK1/2 activation. In SH-SY5Y cells PAC1 
receptor-induced ERK1/2 activation is cAMP-dependent but PKA-independent (Monaghan 
et al., 2008). However, in guinea-pig cardiac neurons (Clason et al., 2016) and N2a cells 
(the current study) PAC1 receptor-induced ERK1/2 signalling is PKA-dependent. Hence, 
PKA-mediated inhibition of TG2 activation may indeed reflect the up-stream role of PKA 
in ERK1/2 activation. Finally, PACAP-27-induced TG2 activation was also sensitive to 
inhibition of PKB and JNK1/2, suggesting a role for these kinases in PAC1 receptor-
induced TG2 activation.  
   We have previously shown that TG2 is phosphorylated following activation of the A1 
adenosine receptor in H9c2 cells (Vyas et al., 2016). The current data demonstrate that 
TG2 is also phosphorylated following PAC1 receptor activation. Furthermore, PAC1 
receptor-induced TG2 phosphorylation was attenuated by pharmacological inhibition of 
MEK1/2, PKA and removal of extracellular Ca2+. It is not clear how the absence of 
extracellular Ca2+ blocks TG2 phosphorylation since PAC1 receptor-induced ERK1/2 
activation is independent of Ca2+ influx. One possible explanation is that changes in 
[Ca2+]i promote conformational changes in TG2 that facilitate its phosphorylation by 
protein kinase(s). Alternatively, Ca2+ influx may play a role in augmenting PAC1 
receptor-induced PLC/PKC signalling. However, the fact that the PKC inhibitor Ro 31-
8220 did not block TG2 phosphorylation, suggests that PKC may regulate other targets 
involved in TG2 activation. The next logical step would be to identify the specific site(s) 
of TG2-associated serine and threonine phosphorylation. Previous studies have shown 
that TG2 is phosphorylated by PKA at Ser215 and Ser216  (Mishra and Murphy, 2006) and 
at an unknown site(s) by PTEN-induced putative kinase 1 (PINK1; Min et al., 2015). At 
present the precise role of PAC1 receptor-induced TG2 phosphorylation is not known. 
However, PKA-mediated phosphorylation of TG2 enhances its interaction with the 
scaffolding protein 14-3-3 and increases TG2 kinase activity, whereas PINK1-mediated 
phosphorylation of TG2 blocks its proteasomal degradation (Mishra and Murphy, 2006; 
Mishra et al., 2007; Min et al., 2015). It is also conceivable that TG2 phosphorylation 
sensitizes TG2 to low levels of intracellular [Ca2+] or alters its subcellular location. Work 
underway will determine the functional consequences of PAC1 receptor-induced TG2 
phosphorylation.  
 
4.4 In situ visualisation of TG2 activity  
Fluorescence microscopy was used to visualise in situ TG2 activity following PAC1 
receptor activation. The results were comparable to PAC1 receptor-induced amine 
incorporation activity observed in vitro. However, given the covalent nature of biotin-X-
cadaverine incorporation into protein substrates, it was surprising to observe that in situ 
TG2 activity returned to basal levels after 40 min. Possible explanations for this include 
reversal of  amine incorporation by TG (Stamnaes et al. 2008), targeting of modified 
proteins for degradation or their rapid removal from the cell. Our previous studies have 
reported the rapid expulsion of biotinylated proteins from H9c2 cells following treatment 
with PMA or forskolin (Almami et al. 2014). It could be that the rapid expulsion of 
biotinylated proteins from N2a cells occurs via exosomes (Kalani et al. 2014). Since N2a 
cells secrete exosomes it will be interest to determine whether amine-labelled proteins 
can be detected in exosomes purified from  cell culture supernatants obtained from  
these cells following PACAP-27 treatment (Chivet et al. 2014). 
 
4.5. Role of TG2 in PAC1 receptor-induced cytoprotection 
Previous studies have shown that TG2 protects human SH-SY5Y neuroblastoma cells 
against heat shock–induced cell death (Tucholski et al., 2001). Similarly, TG2 mediates 
protection of neuronal cells against hypoxia and oxygen/glucose deprivation–induced cell 
death by attenuating the HIF hypoxic response pathway (Filiano et al. 2008). Likewise, 
PACAP is widely recognized as a neuroprotective peptide and potential therapeutic agent 
for the treatment of cerebral ischaemia and various neurodegenerative disorders 
(Reglodi et al., 2011; Lee and Seo, 2014). The mechanisms of PACAP/PAC1 receptor-
induced neuroprotection are complex and involve multiple signalling pathways that 
include PKA, PKB, ERK1/2, NF-кB and Ca2+ mobilization (May et al., 2010; Baxter et al., 
2011; Manecka et al., 2013). In this study we have shown for the first time a role for 
TG2 in PAC1 receptor-induced cytoprotection in differentiating mouse N2a and human 
SH-SY5Y neuroblastoma cells. However, whilst it is not clear how PAC1 receptor-induced 
TG2 activation mediates cell survival, TG2 is known to regulate pathways associated with 
PACAP neuroprotection. For example, TG2 activates adenylyl cyclase and enhances 
cAMP/PKA dependent CRE-reporter gene activity in SH-SY5Y neuroblastoma cells 
(Tucholski and Johnson, 2003) and promotes NF-кB signaling via cross-linking of IкB 
(Erkert et al., 2014). In the current study inhibition of TG2 blocked PACAP-27 mediated 
attenuation of  hypoxia-induced activation of caspase-3. Recent studies have shown that 
TG2 inhibits apoptosis via the down-regulation of the Bax expression and inhibition of 
caspase 3 and 9 (Cho et al., 2010).  Further work is required to determine the role of 
TG2 in PAC1 receptor-induced cell survival.  
 
4.6. Role of TG2 in PAC1 receptor-induced neurite outgrowth 
Previous studies have shown that TG2 is essential for differentiation/neurite outgrowth in 
human neuroblastoma SHSY5Y cells (Tucholski et al., 2001; Singh et al., 2003). 
Mechanisms associated with TG2-induced neurite outgrowth include transamidation of 
RhoA and subsequent activation of ERK1/2 and p38 MAPK (Singh et al., 2003). Similarly, 
PACAP triggers neuronal differentiation of human SH-SY5Y cells via a cAMP-dependent 
but PKA-independent pathway requiring activation of ERK1/2 and p38 MAPK (Monaghan 
et al. 2008). The data presented in this study suggest that pharmacological inhibition of 
TG2 blocks PACAP-27-induced outgrowth of axon-like processes, suggesting the 
involvement of TG2 in PAC1 receptor neurite outgrowth. However, further studies are 
required to identify the downstream substrates of TG2 and signalling pathways 
associated with the role of TG2 in PAC1 receptor neuronal differentiation.    
   In conclusion, our data show for the first time that TG2 activity is regulated by the 
PAC1 receptor in differentiating N2a and SH-SY5Y  cells. Work is currently underway to 
understand more fully the role of TG2 in PAC1 receptor signalling and modulation of 
neuronal cell function.  
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Figure legends 
Figure 1. Protein expression of TG isoforms and neuronal markers in mitotic and 
differentiated N2 cells. Where indicated cells were differentiated with retinoic acid (1 µM) 
or PACAP-27 (100 nM) for 48 h in serum-free medium. (A) Immunocytochemistry by 
fluorescence microscopy was performed using anti-choline acetyltransferase antibody 
(ChAT; cholinergic neuronal marker; green) and anti-tyrosine hydroxylase antibody (TH; 
dopaminergic and noradrenergic neuronal marker) and DAPI counterstain for nuclei 
visualisation (blue). Images presented are from one experiment and representative of 
three. (B) Quantified immunocytochemistry data represent the mean ± S.E.M. of 
fluorescence intensity relative to DAPI stain for five fields of view each from three 
independent experiments. (C) Cell lysates (20 µg protein) from mitotic (M) and 
differentiating (D) N2a cells were analysed for TG1, TG2 and TG3 expression by Western 
blotting using TG isoform specific antibodies. Levels of GAPDH are included for 
comparison.  (D) Quantified data are expressed as the ratio of TG isoform to GAPDH and 
represent the mean  S.E.M. from four independent experiments.  **P<0.01, 
***P<0.001, and ****P<0.0001 versus mitotic cells. 
 
Figure 2: PACAP-27-induced cAMP accumulation in differentiating N2a cells. 
Differentiating N2a cells were treated with the indicated concentrations of PACAP-27 for 
10 min.  Levels of cAMP were determined as described in Materials and Methods. The 
results represent the mean  S.E.M. of three experiments each performed in triplicate. 
*P0.05, **P<0.01, and ****P<0.0001 versus control response. 
 
Figure 3. Effect of PACAP-27 on transglutaminase activity in N2a cells. Differentiating 
N2a cells were either incubated with 100 nM PACAP-27 for the indicated time periods or 
for 10 min with the indicated concentrations of PACAP-27. Cell lysates were then 
subjected to the biotin-cadaverine incorporation (A and B) or protein cross-linking assay 
(C and D). Data points represent the mean TG specific activity ± S.E.M. from four (A and 
C), five (B) or six (D) independent experiments. *P0.05, **P<0.01, ***P<0.001, and 
****P<0.0001 versus control response. 
 
Figure 4. Effect of the selective PAC1 receptor antagonist PACAP 6-38 and inhibitors of  
TG2 and PKA in on PACAP-27 induced TG2 activity in differentiating N2a cells. Cells were 
pretreated for 1 h with the TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) or for 30 
min with the selective PAC1 receptor antagonist PACAP 6-38 (100 nM) or the PKA 
inhibitors KT 5720  (5 µM) or Rp-3’,5’-cAMPs (50 µM) prior to 10 min stimulation with 
PACAP-27 (100 nM). Cell lysates were then subjected to the biotin-cadaverine  
incorporation (A,C,E) or protein cross-linking assay (B,D,F). Data points represent the 
mean TG specific activity ± S.E.M. from four independent experiments. *P0.05, 
***P<0.001, and ****P<0.0001, (a) versus control and (b) versus 100 nM PACAP-27 
alone.   
Figure 5. Effect of PACAP-27 on ERK1/2, PKB and JNK1/2 phosphorylation in 
differentiating N2a cells. Where indicated, N2a cells were pre-treated for 30 min with PD 
98059 (50 µM), SP 600 125 (20 µM) or Akt inhibitor X1 (100 nM, 1 µM or 10 µM) prior to 
stimulation with PACAP-27 (100 nM) for 10 min. Cell lysates were analysed by Western 
blotting for activation of (A) ERK1/2, (B) PKB and (C) JNK1/2 using phospho-specific 
antibodies. Samples were subsequently analysed on separate blots using antibodies that 
recognize total ERK1/2, PKB and JNK1/2. Quantified data are expressed as the 
percentage of the value for control cells (=100%) in the absence of protein kinase 
inhibitor and represent the mean  S.E.M. of four independent experiments. ***P<0.001 
and ****P<0.0001, (a) versus control and (b) versus 100 nM PACAP-27.  
 
Figure 6. Effect of protein kinase inhibitors (PKA, PKC) and Ca2+ on PACAP-27 induced 
ERK1/2 activation. Where indicated, differentiating N2a cells were pre-treated for 30 min 
with (A) KT 5720 (5 µM) or (B) Ro 318220 (10 µM) prior to stimulation with PACAP-27 
(100 nM) for 10 min. (C) cells were  stimulated for 10 min with PACAP-27 (100 nM) 
either in the presence (1.8 mM CaCl2) or absence of extracellular Ca2+ (nominally Ca2+-
free Hanks/HEPES buffer containing 0.1 mM EGTA). Cell lysates were analysed by 
Western blotting for activation of ERK1/2 using a phospho-specific antibody. Samples 
were subsequently analysed on separate blots using an antibody that recognizes total 
ERK1/2. Quantified data are expressed as the percentage of the value for control cells 
(=100%) in the absence of protein kinase inhibitor or presence of extracellular Ca2+ and 
represent the mean  S.E.M. of four independent experiments. ***P<0.001 and 
****P<0.0001, (a) versus control and (b) versus 100 nM PACAP-27. 
 
Figure 7. Effect of protein  kinase inhibitors (ERK1/2, PKC, PKB, JNK1/2) on PAC1  
receptor-induced TG activity. Differentiating N2a cells were pretreated for 30 min with 
PD 98059 (50 µM), Ro 31-8220 (10 µM), Akt inhibitor XI (100 nM) or SP 600125 (20 µM) 
prior to 10 min stimulation with PACAP-27 (100 nM). Cell lysates subjected to biotin-
cadaverine incorporation (A,C,E) or protein cross-linking assay (B,D,F). Data points 
represent the mean ± S.E.M. TG specific activity from four independent experiments. 
*P<0.05, ** P0.01, *** P0.001 and **** P0.0001, (a) versus control and (b) versus 
100 nM PACAP-27 alone. 
 
Figure 8. PACAP-27-induced in situ TG activity in differentiating N2a cells. Cells were 
incubated with 1 mM biotin-X-cadaverine (BTC) for 6 h, after which they were incubated 
with  (A) 100 nM PACAP-27 for 5, 10, 20, or 40 min, (B) the indicated concentrations of 
PACAP-27 for 10 min, or (C) with the PAC1 receptor antagonist PACAP 6-38 (100 nM) for 
30 min or for 1 h with the TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) prior to 10 
min stimulation with PACAP-27 (100 nM). TG2-mediated biotin-X-cadaverine 
incorporation into intracellular proteins was visualized using FITC-conjugated ExtrAvidin® 
(green). Nuclei were stained with DAPI (blue) and viewed using a Leica TCS SP5 II 
confocal microscope (20x objective magnification). Images presented are from one 
experiment and representative of three. Quantified data represent the mean ± S.E.M. of 
fluorescence intensity relative to DAPI stain for five fields of view each from at least 
three independent experiments. *P<0.05, ** P0.01, *** P0.001 and ****P0.0001 
versus control response. 
 
Figure 9. Effect of PACAP-27 on [Ca2+]i and role of Ca2+ in PACAP-27-induced TG2 
activation in differentiating N2a cells. Shown are A) PACAP-27 (100 nM) triggering a 
rapid and transient rise in intracellular Ca2+ in the presence of extracellular Ca2+ (1.3 
mM). B) the absence of Ca2+ responses induced by PACAP-27 during experiments 
performed in nominally Ca2+-free buffer and 0.1 mM EGTA. In these experiments 
depletion of intracellular Ca2+ stores with thapsigargin (5 µM) was still evident. The panel 
letters (a-d) correspond to the time points in the traces. Similar results were obtained in 
three other experiments. For TG2 activity, cells were  stimulated for 10 min with PACAP-
27 (100 nM) either in the presence (1.8 mM CaCl2) or absence of extracellular Ca2+ 
(nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA). Cell lysates were 
subjected to biotin-cadaverine incorporation assay (C) or protein cross-linking assay (D). 
Data points represent the mean TG specific activity ± S.E.M. from four independent 
experiments. ** P0.01, *** P0.001 and **** P0.0001, (a) versus control in presence 
of extracellular Ca2+, (b) versus 100 nM PACAP-27 in presence of extracellular Ca2+.  
  
Figure 10. Effect of the MEK1/2 inhibitor PD 98059 on PACAP-27-induced 
phosphorylation of TG2. Where indicated, differentiating N2a cells were pre-treated for 
30 min with PD 98059 (50 µM) prior to stimulation with PACAP-27 (100 nM) for 10 min. 
Following stimulation with PACAP-27, cell lysates were subjected to immunoprecipitation 
using anti-TG2 monoclonal antibody as described under “ Materials and Methods”. The 
resultant immunoprecipitated protein(s) were subjected to  SDS-PAGE and Western blot 
analysis using (A) anti-phosphoserine and (B) and anti-phosphothreonine antibodies. 
One tenth of the total  input was applied to the first lane to show the presence of 
phosphorylated proteins prior to immunoprecipitation and negative controls with the 
immunoprecipitation performed with immunobeads only were included to demonstrate 
the specificity of the band shown. Quantified data for PACAP-induced increases in TG2-
bound serine and threonine phosphorylation are expressed as a percentage of the  TG2 
phosphorylation observed in control cells (=100%). Data points represent the mean  
S.E.M. from three independent experiments.  *P0.05, **P0.01, and ***P0.001, (a) 
versus control and (b) versus 100 nM PACAP-27 alone.   
 
Figure 11. Effect of the PKA inhibitor KT 5720 on PACAP-27-induced phosphorylation of 
TG2. Where indicated, differentiating N2a cells were pre-treated for 30 min with KT 5720 
(5 µM) prior to stimulation with PACAP-27 (100 nM) for 10 min. Following stimulation 
with PACAP-27, cell lysates were subjected to immunoprecipitation using anti-TG2 
monoclonal antibody as described under “ Materials and Methods”. The resultant 
immunoprecipitated protein(s) were subjected to  SDS-PAGE and Western blot analysis 
using (A) anti-phosphoserine and (B) and anti-phosphothreonine antibodies. One tenth 
of the total  input was applied to the first lane to show the presence of phosphorylated 
proteins prior to immunoprecipitation and negative controls with the 
immunoprecipitation performed with immunobeads only were included to demonstrate 
the specificity of the band shown. Quantified data for PACAP-induced increases in TG2-
bound serine and threonine phosphorylation are expressed as a percentage of the  TG2 
phosphorylation observed in control cells (=100%). Data points represent the mean  
S.E.M. from three independent experiments.  *P0.05, **P0.01, and ***P0.001, (a) 
versus control and (b) versus 100 nM PACAP-27 alone.   
 
Figure 12. Effect of simulated hypoxia on MTT reduction, LDH release and caspase 3 
activity in differentiating N2a cells. Cells in glucose- and serum-free DMEM were exposed 
to hypoxia (1% O2) for the indicated periods of time. Cell viability was assessed by 
measuring (A) the metabolic reduction of MTT by cellular dehydrogenases, (B) release of 
LDH into the culture medium and (C) caspase-3 activity via Western blot analysis using 
anti-active caspase 3 antibody. (D) Quantified caspase-3 activity data. Data are 
expressed as the percentage of the normoxic control (=100%) and represent the mean  
S.E.M. from four independent experiments, each performed in (A) quadruplicate or (B) 
sextuplicate. *P0.05, ***P0.0001 and **** p0.0001 versus normoxic control. 
Figure 13. The effect of PACAP-27 on hypoxia-induced cell death in N2a  cells. 
Differentiating N2a cells were pre-treated with the PAC1 receptor antagonist PACAP 6-38 
(100 nM) for 30 min before the addition of PACAP-27 (100 nM) for 10 min prior to 8 h 
hypoxia (1% O2) or 8 h normoxia. Cell viability was assessed by measuring (A) the 
metabolic reduction of MTT by cellular dehydrogenases, (B) release of LDH into the 
culture medium and (C) caspase-3 activity via Western blot analysis using anti-active 
caspase 3 antibody. (D) Quantified caspase-3 activity data. Data are expressed as a 
percentage of normoxia control cell values (=100%) and represent the mean  S.E.M. 
from four independent experiments, each performed in (A) quadruplicate or (B) 
sextuplicate. ****P0.0001, (a) versus normoxia control, (b) versus hypoxia control (c) 
versus 100 nM PACAP-27 in the presence of hypoxia. 
 
Figure 14. The effects of the TG2 inhibitors Z-DON and R283 on PACAP-27 induced cell 
survival in N2a cells. Differentiating N2a cells were pre-treated for 1 h with the TG2 
inhibitors Z-DON (150 µM) or R283 (200 µM) before the addition of PACAP-27 (100 nM) 
for 10 min prior to 8 h hypoxia (1% O2) or 8 h normoxia. Cell viability was assessed by 
measuring (A) the metabolic reduction of MTT by cellular dehydrogenases, (B) release of 
LDH into the culture medium and (C) caspase-3 activity via Western blot analysis using 
anti-active caspase 3 antibody. (D) Quantified caspase-3 activity data. Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean  S.E.M. from four independent experiments each performed in (A) quadruplicate 
and (B) sextuplicate. *P<0.05, **P0.01, ***P0.0001 and ****P0.0001, (a) versus 
normoxia control, (b) versus hypoxia control (c) versus 100 nM PACAP-27 in the 
presence of hypoxia. 
Figure 15. Effect of PACAP-27 on transglutaminase activity in human SH-SY5Y 
neuroblastoma cells. Differentiating SH-SY5Y cells were either incubated with 100 nM 
PACAP-27 for the indicated time periods or for 30 min with the indicated concentrations 
of PACAP-27. Cell lysates were then subjected to the biotin-cadaverine incorporation (A 
and B) or protein cross-linking assay (C and D). Data points represent the mean TG 
specific activity ± S.E.M. from four (A and C) or three (B and D) independent 
experiments. *P0.05, **P<0.01, ***P<0.001, and ****P<0.0001 versus control 
response. 
Figure 16. The effect of PACAP-27 on hypoxia-induced cell death in human SH-SY5Y  
cells. Differentiating SH-SY5Y cells were pre-treated either with the PAC1 receptor 
antagonist PACAP 6-38 (100 nM) for 30 min (panels A-D) or with the TG2 inhibitors Z-
DON (150 µM) or R283 (200 µM) for 1 h (panels E-H) before the addition of PACAP-27 
(100 nM) for 10 min prior to 8 h hypoxia (1% O2) or 8 h normoxia. Cell viability was 
assessed by measuring the metabolic reduction of MTT by cellular dehydrogenases 
(panels A,E), release of LDH into the culture medium (panels B,F)  and caspase-3 
activity via Western blot analysis using anti-active caspase 3 antibody (panels C,G). 
Quantified caspase-3 activity data is shown in panels D and H. Data are expressed as a 
percentage of normoxia control cell values (=100%) and represent the mean  S.E.M. 
from four independent experiments each performed in (A,E) quadruplicate and (B,F) 
sextuplicate. *P<0.05, **P0.01, ***P0.0001 and ****P0.0001, (a) versus normoxia 
control, (b) versus hypoxia control (c) versus 100 nM PACAP-27 in the presence of 
hypoxia. 
Figure 17. The effect of TG2 inhibitors on PACAP-27 induced outgrowth of axon-like 
processes in differentiating N2a cells. (A) N2a cells were incubated for 1 h with the TG2 
inhibitors Z-DON (150 µM) or R283 (200 µM) before  treatment with PACAP-27 (100 nM) 
in serum-free DMEM for 48 h. Following stimulation the cells were fixed and stained with 
Coomassie blue. (B) Quantified data points represent the number of axon-like processes 
determined as described in Materials and Methods. Shown are the mean number of 
axons/100 cells  S.E.M. from four independent experiments each performed in 
quadruplicate. White arrows indicate typical axon-like processes. ***P0.0001 and 
****P0.0001, (a) versus mitotic control, (b) versus 100 nM PACAP-27 alone.  
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